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Summary The cyclin-dependent kinase inhibitor p16gene (P16, MTS1, CDKN2) has been shown to be altered by deletion or point mutation
in some human tumours and cancer cell lines, suggesting that it works as a tumour suppressor. We analysed p16 gene mutation and p16
protein expression in 42 primary ovarian carcinomas and in five human ovarian cancer cell lines. Polymerase chain reaction (PCR)
amplifications of exons 1 and 2 of the gene showed no deletion or gross rearrangement in the p16 gene. The lack of deletion was further
demonstrated by Southern blot analysis. Looking for point mutations, we used single-strand confirmation polymorphism (SSCP) analysis and,
in half of the tumours, we sequenced both strands of exons 1 and 2. No mutations were detected. In 11 out of 42 patients (26%), however, we
detected no protein expression by Western blot analysis, suggesting that decreased expression of p16 rather than deletion of the gene can
occur in a significant percentage of human ovarian cancers. In the same experiment CDK4 protein was found homogeneously expressed in
all the tumour specimens and in the five cell lines. The lack of expression of p16 was not due to hypermethylation of the gene assessed by
digestion of genomic DNAs with a methylation sensitive enzyme, suggesting that other mechanisms, not yet identified, are involved in the
decreased expression of the p16gene in human ovarian tumours.
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The progression of the mammalian cell cycle is regulated by a
complex network involving cyclins and a family ofprotein kinases
known as cyclin-dependent kinases (cdks) (Sherr, 1994; Pines,
1995). The interaction between cyclins and cdk is controlled by
proteins called cdk inhibitors, which include p21, p27, p57, p16,
p15 and p18 (Sherr and Roberts, 1995). These bind and inactivate
or destroy the preformed cyclin-cdk complex (Sherr and Roberts
1995). All the cdk inhibitors have been proposed as tumour
suppressors for their ability to block the cell cycle and arrest the
growth of deregulated cancer cells. Both p2] and p27 are rarely
mutated in different tumour types (Shiohara et al, 1994; Kawamata
et al, 1995) whereasp16 andp15 are frequently deleted or mutated
in many tumours of different origin (Kamb et al, 1994; Nobori et
al, 1994). Thep]6 gene maps on chromosome 9p21, aregion asso-
ciated with a frequent loss of heterozygosity in different tumours
including gliomas, leukaemia, melanoma and head and neck
carcinomas (Okamoto et al, 1994).
A high frequency of homozygous deletion of p16 has been
reported in human cancer cell lines derived from many different
tumour types (Kamb et al, 1994; Nobori et al, 1994). However, the
incidence of mutations or deletions in primary tumours is much
lower than in cell lines (Cairns et al, 1994; Spruck et al, 1994;
Zhang et al, 1994). Mutations and homozygous deletion of pl6
have been reported in melanoma, glioblastoma, pancreatic adeno-
carcinoma, bladder carcinoma, non-small-cell lung cancer, acute
lymphocytic leukaemia, chronic myeloid leukaemia and non-
Hodgkin's lymphoma (Hirama and Koeffler, 1995; Sheaff and
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Roberts, 1995). It was initially reported that the p16 gene was
homozygously deleted in two out of seven ovarian cancer cell
lines (Kamb et al, 1994), but a lower incidence was recently found
in primary tumours (Campbell et al, 1995; Rodabaugh et al, 1995;
Schultz et al, 1995; Devlin et al, 1996).
Here we report the genomic analysis ofp16 and the level ofp16
expression in 42 primary ovarian cancers and, for comparison, in
five human ovarian cancer cell lines. The studies were conducted in
parallel with CDK4, which has been reported to be overexpressed
in some tumour samples expressing normalp16 (He et al, 1994).
MATERIALS AND METHODS
Cell lines
The human ovarian cancer cell lines OVCAR-3, SW626, SKOV-3
and IGROV were grown in RPMI-1640 medium supplemented
with 10% fetal calf serum (FCS). The human ovarian cancer cell
line COR, recently isolated in our laboratory, was grown in F12
Ham supplemented with 10% FCS.
Patient characteristics
Tumoursamples wereobtainedfrom42ovariancancerpatients (21%
stage I, 10% stage II, 62% stage III and 7% stage IV). Histological
types were: serous 60%, endometrioid 10%, clear cell 5%, mucinous
5% and undifferentiated 20%. Regarding the grade, 76% of the
tumours were G3, 16% G2, 8% GI and 5% were borderline.
The stage and the histological grading of the primary tumours
were defined according to the FIGO criteria.
Fresh tumourtissues were obtained atfirstlaparatomy before any
othertreatment. The tissues were freed from necrotic, haemorrhagic
and connective tissue, minced and stored at -80°C in cryotubes
(Nunc) until processed.
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system (Amersham). Each sample was tested at least twice in
separate experiments.
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Figure 1 Ethidium bromide-stained agarose gel of PCR amplified p16 exon
2 and j-actin gene in 42 ovarian carcinomas
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Figure 2 Representative Southern blot analysis of p16. DNA extracted from
ovarian carcinomas was digested with EcoRI. The same filter was first
probed with p16 cDNA and successively with a-actin c-DNA. Numbers
represent the patient's number
Southern analysis
Genomic DNA was isolated from cell lines and tumour specimens
according to standard procedures (Sambrook et al, 1989). An
aliquot of 10 gig of DNA was digested to completion with either
EcoRI or EcoRI and SacII and fractionated through 1% agarose
gel, blotted onto nylon membranes and hybridized with 32P_
labelled probes obtained by random priming using a Rediprime kit
(Amersham). The probes used were p16 c-DNA (kindly supplied
by Dr D Beach, Cold Spring Harbor Laboratory, NY, USA), pH6
exon (obtained by PCR, see below) and cx-actin cDNA. After
hybridization at 420C overnight, filters were washed twice in
2 x SSC at room temperature and once at 650C in 2 x SSC and
1% sodium dodecyl sulphate (SDS) and then autoradiographed.
Western blot analysis
Frozen tumour samples were pulverized, then lysed in a solution
containing 0.1 sodium chloride, mm Tris-HCI pH 7.6, 1 mm
EDTA, jg m1 aprotinin, gg ml-' leupeptin, 100 jg
phenylmethylsulphonyl flouride (PMSF), centrifuged for 5 mmn at
12 g at 40C and protein concentration was measured with Bio-
Rad protein assay (BioRad); 100 jig of proteins were mixed with
an equal volume of 2 x loading buffer (0.1Im Tris-HCI pH 6.8, 4%
SDS, 0.2 m dithiothreitol. 0.2% bromophenol blue and 20% glyc-
erol), boiled, size-fractionated through SDS/15% polyacrylamide
gels and blotted onto nitrocellulose filters (Schleyer & Schull).
Filters were hybridized with polyclonal antibodies against p1I6 and
CDK4 (Santa Cruz Biotechnology) and revealed with the ECL
PCR, PCR-SSCP and sequencing
Primers foramplification ofexons 1 and 2 ofp16 were constructed
on the basis of the published sequence (Kamb et al, 1994;
Campbell et al, 1995). The p16 gene homozygous deletion was
investigated by PCR for the ability to amplify a region ofthe gene
compared with the ability to amplify, as an internal control, the
human ,-actin gene.
The sequences of the primers used for PCR, SSCP and DNA
sequencing were: p16 exon 1, sense 5'-GAAGAAAGAG-
GAGGGGG and antisense 5'-GCGCTACCTGATTCCAATTC;
p16 exon 2, sense 5'-ACAAGCTTCCTITlTCCGTCAT and
antisense 5'-TCTGAGCTTTGGAAGCTCTC. The sequence of
the primers used for multiplex PCR were p16 exon 2, sense
5'-TCTGACCATTCTGTTCTCTC and antisense 5'-AGCAC-
CACCAGCGTGTC; j-actin, sense 5'-CTTCCTGGGCATG-
GAGTCCT and antisense 5'-GGAGCAATGATCTTGATCTT.
These primers amplify fragments of 340, 422, 166 and 202 bp
respectively; 100 ng of genomic DNA was amplified in a final
volume of 50 pl of PCR Gold buffer (Perkin Elmer), containing
150 nmol ofprimers and 1.5 units ofAmpli-Taq Gold polymerase
(Perkin-Elmer). The cycles of amplification were as described
previously (Kamb et al, 1994) and reduced to 30 in the 0-actin co-
amplification to maintain the amplification in the exponential
phase (Campbell et al, 1995). Samples were loaded on 4% agarose
gel and visualized by ethidium bromide staining. Exon 3 (11 bp)
was not analysed.
For SSCP analysis amplification conditions were the same
except for the presence of 1 jCi of [32P]dCTP (Amersham).
Samples were diluted 1:4 with 0.1% SDS/10 mM EDTA and
further mixed 1:1 with a stop solution consisting of 95%
formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05%
xylene cyanol, heated for 5 min at 95°C, chilled on ice and imme-
diately loaded on 6% acrylamide gels containing 10% glycerol.
For exon 2 samples were digested with SmaI (New England
Biolabs) before loading.
DNA sequencing of both strands was performed using the
Sequenase PCR product sequencing kit (Amersham).
RESULTS
Forty-two ovarian primary tumours, at different malignant stage,
were examined by PCR for the possibility ofhomozygous deletion
in the p1 6 gene (exon 1 and 2). In all the tumour samples and in the
five cell lines examined, the fragments ofexpected size for exons
1 and 2 (respectively of 340 and 422 bp) could be amplified (data
not shown). In order to exclude that the amplified fragments could
be due to the presence ofcontaminating normal cells in the tumour
specimen, we performed a multiplex PCR with the ,-actin as an
internal control with a reduced number of cycles (see Materials
and methods).
Figure 1 reports the data obtained on the 5' halfof exon 2, where
the majority of p16 mutations in human cancer cells have been
described (Maestro et al, 1995). Moreover, under these conditions
no deletions could be found. Each tumour was examined in at least
two independent experiments and small variations were observed
in the relative intensities of the human P-actin and p16 bands
among the experiments.
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Figure 3 Detection of p16 and CDK4 expression by Western blot analysis.
(A) Lanes 1-18, protein extracts from ovarian carcinomas. Others are
OVCAR-3, SKOV-3, IGROV, SW626 and COR cell lines. Total protein extract
(100 jug) was loaded per lane. (B) p16 and CDK4 expression in 24 additional
ovarian tumours
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Figure 4 Double (EcoRl and Sac 11) digestion of genomic DNA obtained
from tumours expressing or not expressing p16 protein. Filters were
hybridysed with exon 1 probe of p16 obtained by PCR
To confirm PCR analysis we performed Southern blotting on
the EcoRI-digested DNA from all the tumours. A representative
experiment is shown in Figure 2 (top). A predominant 4.3-kbp
band was found after hybridization with piS c-DNA. A second,
less intense band of approximately 6 kbp was found, which is
likely to be cross-hybridization with p15 (Kamb et al, 1994). All
the tumour specimens presented the band of the expected
molecular weight with non-significant reduction in the pieS signal
compared with the control human a-actin gene (Figure 2, bottom).
These data confirm the PCR results, suggesting that no deletions
or gross rearrangements are found on the pieS gene-.
We then screened genomic DNA for point mutations in exons
and 2 of the pieS gene by SSCP analysis with the same set of
primers and PCR conditions (data not shown). Any suspect, differ-
ently migrating band was considered as potentially indicative of
a mutation in the DNA sequence. In half (21) of the tumour
specimens both strands ofeach exon were sequenced and analysed
for mutations. We could not detect mutations in both exons in any
ofthe DNA samples analysed.
We then evaluated p16 and CDK4 (p34) protein expression by
Western blotting (Figure 3) using specific antibodies with no cross-
reactivity with other cdks and cdk inhibitors. The p16 protein was
undetectable in 11 outof42patients andinthree outoffivecell lines
(OVCAR-3, SKOV-3 and SW626), whereas the CDK4 protein was
detected in all theprimary tumours with a low degree ofinterpatient
variation, and in all the five ovarian carcinoma cell lines examined.
To verify whether the lack ofp16 expression in 26% (11 out of
42) of primary ovarian tumours was due to hypermethylation of
the p16 gene, we digested genomic DNAs with either EcoRI and
the methylation-sensitive enzyme SacII. The presence of hyper-
methylation in exon 1 is demonstrated by the presence ofa4.3-kbp
band (which results from digestion with EcoRI alone) whereas the
presence of a 3.3-kbp band is indicative of digestion with both
enzymes. Figure 4 reports that in all the tumours tested the double
digestion resulted in the formation ofthe 3.3-kbpfragment with no
evidence of hypermethylation. In patient number 13 a smaller
band appeared that, however, is likely to be an artefact as it was
not observed in the EcoRI-digested samples (see Figure 2).
DISCUSSION
Activation of oncogenes and inactivation or deletion of tumour-
suppressor genes are events involved in malignant transformation
and tumour progression.
Recently aG, cdk inhibitor (p16) has been cloned and shown to
map in a region of chromosome 9 (9p2l) frequently associated
with loss of heterozygosity in different human tumour types
(Okamoto et al, 1994). The high frequency of deletion of the p16
gene in tumour cell lines strongly suggested its role as a tumour-
suppressor gene and recent data reported the ability ofpi6, once
introduced into tumour cells, to arrest proliferation by blocking
cells inG, (Jin et al, 1995; Quelle et al, 1995).
In ovarian tumourspi6was initially found deleted in two out of
seven cell lines (Kamb et al, 1994). More recently, however, little
or no deletion of p16 in primary tumours has been observed
(Campbell et al, 1995; Rodabaugh et al, 1995; Schultz et al, 1995;
Devlin et al, 1996), suggesting that pi6 abnormalities were a
secondary event selected for during the establishment ofcell lines
(Beijersbergen and Bernards, 1996).
In our study none ofthe tumours analysed presented deletion or
point mutations ofthepi6gene. Our data are further supported by
the finding that the analysis of ten additional human ovarian
tumours transplanted into nude mice did not show evidence of
deletion ofp]6 (unpublished data).
Our results, together with those already published, indicate that
in human ovarian carcinomapl6 structural gene alterations are not
involved in the pathogenesis ofthis malignancy.
No data on p16 protein expression in ovarian tumours are
available. It has been reported that in human ovarian cancer cell
lines retaining thep16 gene mRNA forp]6 was present (Schultz et
al, 1995). In fresh human samples down-regulation ofp16 mRNA
was found in only 1 out of 11 ovarian carcinomas (Rodabaugh
etal, 1995).
In the present study, wefound thatp16 protein was not detectable
in 26% (11 out of 42) of primary tumours and in three cell lines
growing in vitro. Lack of expression was not able to be correlated
with the tumour stage, tumourgrade or histological type.
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The inactivation of the pi6 gene transcription without altering
its primary structure could be due to the methylation on the CpG
islands spanning exon 1 and part of exon 2 (Merlo et al, 1995;
Nishikawa et al, 1995). This process, which appears comparable
with genetic imprinting, has been found in different tumours
(Beijersbergen and Bernards, 1996) that had previously shown no
p16 gene modification.
In our study we found that ovarian tumours, without p16 protein
expression, did not reveal hypermethylation ofpl6 promoter, and
that other mechanisms, not yet identified, of p16 silencing are
likely to occur. In particular, the possibility exists that a different
protein resulting from an alternative reading frame usage (p19ad in
mouse) (Beijersbergen and Bernards, 1996; Li et al, 1996) could
be expressed in these patients. The lack of specific antibodies for
this human alternative protein, however, did not allow us to study
this possibility. An alternative way would be to analyse for the
presence of alternative rmRNA in ovarian cancer patients and this
is at present under investigation (the limited amount of tumour
samples obtained allowed us to simultaneously analyse in the
same patients only DNA and proteins). Preliminary data obtained
by RT-PCR using specific primers as described (Stone et al, 1995),
however, showed that the n-transcript was present in only one of
the three cell lines not expressing p16 (data not shown). A definite
conclusion cannot be drawn from these results, considering the
differences already observed between cell lines in culture and
primary tumours at the level of mutation or deletion for the p16
gene (Spruck et al, 1994).
It has been reported that cancer cells with normalp16 gene can
overexpress and amplify CDK4 as an alternative way to interfere
with cell growth regulation (He et al, 1994). This mechanism does
not seem to play a role in ovarian cancer as we found homoge-
neous expression ofCDK4 protein either in primary tumours or in
the five human ovarian cancer cell lines tested. In conclusion, the
lack of expression found on p16 protein in a relatively high
percentage of human tumours could be an important factor in the
development ofovarian cancer.
ACKNOWLEDGEMENTS
This work was performed in memory ofNerina and Mario Mattioli
and was partially supported by CNR 96.01026.ST74. The
generous contribution of the Italian Association for Cancer
Research (AIRC) is gratefully acknowledged. SM is recipient ofa
fellowship from the Italian Association for Cancer Research.
REFERENCES
Beijersbergen RL and Bemards R (1996) Cell cycle regulation by the retinoblastoma
family ofgrowth inhibitory proteins. Biochim Biophys Acta 1287: 103-120
Caims P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, Van Der Riet P,
Blaugrund JE and Sidransky D (1994) Rates ofp16 (MTS1) mutations in
primary tumors with 9p loss. Science 265: 415-417
Campbell IG, Beynon G, Davis M and Englefield P (1995) LOH and mutation
analysis ofCDKN2 in primary human ovarian cancer. IntJ Cancer 63:
222-225
Devlin J, Elder PA, Gabra H, Steel CM and Knowles MA (1996) High frequency of
chromosome 9 deletion in ovarian cancer: evidence for three tumor-suppressor
loci. BrJ Cancer 73: 420-423
He J, Allen JR, Collins VP, Allalunis Turner MJ, Godbout R, Day RS and James CD
(1994) CDK4 amplification is an alternative mechanism to p16 gene
homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807
Hirama T and Koeffler HP (I1995) Role ofthe cyclin-dependent kinase inhibitors in
the development ofcancer. Blood 86: 841-854
Jin XM, Nguyen D, Zhang WW, Kyritsis AP and Roth JA (1995) Cell cycle arrest
and inhibition of tumor cell proliferation by the p16 (INK4) gene mediated by
an adenovirus vector. Cancer Res 55: 3250-3253
Kamb A, Gruis NA, Weaver Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert
E, Day RS, Johnson BE and Skolnick MH (1994) A cell cycle regulator
potentially involved in genesis ofmany tumor types. Science 264: 436-440
Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S,
Hatta Y, Simpson J, Wilcyznski S, Lee YY, Bartram CR and Koeffler HP
(1995) Molecular analysis ofthe cyclin-dependent kinase inhibitor gene
p27/KipI in human malignancies. CancerRes 55: 2266-2269
Li R, Hannon GJ, Beach D and Stillman B (1996) Subcellular distribution ofp21
and PCNA in normal and repair-deficient cells following DNA damage. Curr
Biol 6: 189-199
Maestro R and Boiocchi M (1995) Sunlight and melanoma: an answer from MTSI
(pI6). Science 267: 15-16
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and
Sidransky D (1995) 5' CpG island methylation is associated with
transcriptional silencing ofthe tumour suppressorp16/CDKN2/MTS I in
human cancers. Nature Med 1: 686-692
Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK and Huang HJS
(1995) Loss ofP16(INK4) expression is frequent in high grade gliomas.
CancerRes 55: 1941-1945
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA (1994) Deletions
ofthe cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.
Nature 368: 753-756
Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP,
Forrester K, Gerwin B, Serrano M, Beach DH and Harris CC (1994) Mutations
and altered expression ofpl6INK4 in human cancer. Proc NatlAcadSci USA
91:11045-11049
Pines J (1995) Cyclins and cyclin-dependent kinases: theme and variations. Adv
Cancer Res 66: 181-212
Quelle DE, Ashmun RA, Hannon GJ, Rehberger PA, Trono D, Richter KH,
Walker C, Beach D, Sherr CJ and Serrano M (1995) Cloning and
characterization of murine pl6(INK4a) and pl5(INK4b) genes. Oncogene 11:
635-645
Rodabaugh KJ, Biggs RB, Qureshi JA, Barrett AJ, Welch WR, Bell DA, Berkowitz
RS and Mok SC (1995) Detailed deletion mapping ofchromosome 9p and p16
gene alterations in human borderline and invasive epithelial ovarian tumors.
Oncogene 11: 1249-1254
Sambrook J, Fritsch EF and Maniatis T (1989) Molecular Cloning: A Laboratory
Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY
Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC and
Godwin AK (1995) Characterization ofchromosome 9 in human ovarian
neoplasia identifies frequent genetic imbalance on 9q and rare alterations
involving 9p, including CDKN2. CancerRes 55: 2150-2157
SheaffRJ and Roberts JM (1995) Tumor suppression: lessons inp16 from phylum
Falconium. CurrBiol 5: 28-31
Sherr CJ (1994) GI phase progression: cycling on cue. Cell 79: 551-555
Sherr CJ and Roberts JM (1995) Inhibitors ofmammalian G1 cyclin-dependent
kinases. Genes Dev 9: 1149-1163
Shiohara M, El Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL,
Vogelstein B and Koeffler HP (1994) Absence ofWAFI mutations in a variety
ofhuman malignancies. Blood84: 3781-3784
Spruck CH, Gonzalez Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F,
Tsai YC and Jones PA (1994) p16 gene in uncultured tumours. Nature 370:
183-184
Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G and
Kamb A (1995) Complex structure and regulation ofthe P16 (MTSI) locus.
CancerRes 55: 2988-2994
Zhang SY, Klein Szanto AJ, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T,
Carson DA, Ridge JA and Goodrow TL (1994) Higher frequency ofalterations
in the pI6/CDKN2 gene in squamous cell carcinoma cell lines than in primary
tumors ofthe head and neck. CancerRes 54: 5050-5053
C Cancer Research Campaign 1997 British Journal ofCancer (1997) 76(2), 146-149